AI in Medical Field: Hong Kong Company Takes First AI-Generated Drug Candidate To Clinic Targeting Chronic Lung Disease
Portfolio Pulse from Vandana Singh
Hong Kong-based biotech company Insilico Medicine has initiated a Phase 2 clinical trial for the first-ever AI-generated drug, INS018_055, targeting idiopathic pulmonary fibrosis (IPF), a chronic lung disease. The drug was developed using AI at 10% of the traditional cost and in a third of the time. The company used PandaOmics to identify disease-causing targets and Chemistry42 to design new molecules. If successful, the drug could potentially address the limitations of current treatments.
June 28, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Insilico Medicine's use of AI in drug development could potentially impact AIQ, an ETF that invests in AI and big data companies.
AIQ invests in companies that are involved in the AI and big data sector. Insilico Medicine's success in using AI for drug development could potentially increase the value of companies in this sector, thereby positively impacting AIQ.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Insilico Medicine's use of AI in drug development could potentially impact BOTZ, an ETF that invests in robotics and AI companies.
BOTZ invests in companies that are involved in the robotics and AI sector. Insilico Medicine's success in using AI for drug development could potentially increase the value of companies in this sector, thereby positively impacting BOTZ.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Insilico Medicine's use of AI in drug development could potentially impact IRBO, an ETF that invests in robotics and AI companies.
IRBO invests in companies that are involved in the robotics and AI sector. Insilico Medicine's success in using AI for drug development could potentially increase the value of companies in this sector, thereby positively impacting IRBO.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Insilico Medicine's use of AI in drug development could potentially impact ROBO, an ETF that invests in robotics and AI companies.
ROBO invests in companies that are involved in the robotics and AI sector. Insilico Medicine's success in using AI for drug development could potentially increase the value of companies in this sector, thereby positively impacting ROBO.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70